Jessica Dundas
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 174 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Novo Nordisk at 26.2% of the total. Reporting peaked in 2022 at $1,260 and has fallen 77.5% since, to $284 in 2025.
Across 174 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$776
- AbbVie$327
- Lilly USA, LLC$247
- Boehringer Ingelheim$156
- Sanofi-aventis U.S. LLC$151
- Boston Scientific$141
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,957100%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $776 |
| AbbVie | 26 | $327 |
| Lilly USA, LLC | 15 | $247 |
| Boehringer Ingelheim | 10 | $156 |
| Sanofi-aventis U.S. LLC | 9 | $151 |
| Boston Scientific | 1 | $141 |
| Johnson & Johnson | 7 | $126 |
| Bayer | 6 | $117 |
| Supernus Pharmaceuticals, Inc. | 1 | $103 |
| Amarin Pharma, Inc. | 4 | $87 |
| Merck | 4 | $73 |
| Kowa Pharmaceuticals America, Inc. | 4 | $72 |
| Astellas Pharma US Inc | 4 | $64 |
| Amgen | 4 | $61 |
| Esperion Therapeutics, Inc. | 4 | $56 |
| Smith+Nephew | 2 | $42 |
| AstraZeneca | 2 | $38 |
| Hikma Pharmaceuticals USA | 2 | $36 |
| Pfizer | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| GSK | 2 | $28 |
| Mylan Specialty L.p. | 1 | $22 |
| Exact Sciences | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Acerus Pharmaceuticals Corporation | 1 | $15 |
| Shield Therapeutics Inc | 1 | $15 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL PAIN MANAGEMENT$141
- QELBREE$103
How this compares
$2,961 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Other family in Bryan
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
- Stephanie RodriguezCorpus Christi$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.